Brenice Duroseau was interviewed on ABC 7 News Morning WJLA a Washington DC new station by Carolanna Feltner on August 6th to discuss the importance of the new injectable PrEP for women. Lenacapavir was given FDA approval on June 18, 2025. Data from the Phase 3 PURPOSE 1 and PURPOSE 2 studies showed >99.9% of participants enrolled in these trials remained negative for HIV. Lenacapavir is a twice yearly injection.
